Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
Related Posts
Swisscom’s $9 Billion Vodafone Italia Buy Probed by Regulator
The Italian competition regulator has opened an in-depth investigation into Swisscom’s acquisition of Vodafone Italia.
EU to Move Ahead With New Tariffs on Chinese-Made EVs
The bloc approved import fees of up to 45%, defying pleas from some European auto executives who fear retaliation from Beijing.
Elon Musk’s $46 Billion Pay Package: How Tesla Shareholder Approval Could Play Out in Court
- staff
- June 13, 2024
- 0
The carmaker’s CEO says so far, shareholders were approving the package by a wide margin. But a vote to reapprove the agreement is unlikely to […]